titanpharm.com (TTNP) Cash Money per Share

Titan Pharmaceuticals Inc. - graphic logo of issuer TTNP

Cash per share for Titan Pharmaceuticals (TTNP) exhibits volatile dynamics, with the 2.09 level serving as a critical mark. Growth is supported by licenses for prolonged drug delivery for Parkinson's disease. Stable demand for addiction treatment minimizes the impact of crises, although an acute capital shortage and challenges with implant commercialization significantly weaken the company's market position.

Titan Pharma (TTNP) - Cash per Share from 07/04/2022 to 10/18/2025

Analytical breakdowns for Titan Pharmaceuticals

- cash availability and cash flow indicators:
Summary company analysis:TTNP, Titan Pharmaceuticals, Inc.
Flagship merchandise of Titan Pharmaceuticals

Investors utilize this screening to assess the issuer's internal liquidity and solvency. The metric is calculated by dividing the total volume of cash and cash equivalents by the number of shares outstanding. For Titan Pharmaceuticals (TTNP), this metric determines the resource base for the development of implants for opioid addiction therapy. The trend of cash per share over the period demonstrates the business's actual resilience to market shocks.